Recce Pharmaceuticals (RCE) Investor presentation summary

Company overview and market opportunity

• Focuses on anti-infective therapies addressing antibiotic resistance and multidrug-resistant bacteria, with multiple clinical indications and formulations in development.

• Lead product, RECCE® 327 Gel, is in Phase 3 trials for diabetic foot infections (DFI) in Australia and Indonesia, targeting commercialisation in 2027.

• Signed a non-binding 10-year exclusive licensing term sheet with a major Middle Eastern pharmaceutical company.

• Agreements with US Defense agencies and WHO recognition highlight global relevance and support.

• The global DFI market is valued at $5.8B, with anti-infectives market opportunities estimated at $135.4B.

Product pipeline and clinical progress

• Phase 3 clinical trials underway in Indonesia and Australia for RECCE® 327 Gel, with interim data expected in Q3 2026.

• Expanded trial protocols now include both mild and moderate DFI, increasing patient pool and regulatory reach.

• Additional programs target hospital-acquired pneumonia, burn wound infections, and urinary tract infections.

• Previous Phase I/II and II trials for DFI, burn wounds, and ABSSSI achieved all primary and secondary endpoints, demonstrating safety and efficacy.

Scientific innovation and clinical advantages

• RECCE® 327 demonstrates broad-spectrum, rapid bactericidal activity against ESKAPE pathogens, with no observed resistance after 25+ repeats.

• Unique mechanism targets bacterial ATP production, killing both active and resting bacteria quickly.

• Maintains efficacy in urine, suggesting potential for UTI and urosepsis treatment.

• Faster acting than existing antibiotics, with rapid onset and no need for prolonged exposure.